Impact of screening on cervical cancer incidence in England: a time trend analysis.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
24 01 2019
Historique:
entrez: 26 1 2019
pubmed: 27 1 2019
medline: 20 2 2020
Statut: epublish

Résumé

To better model underlying trends in cervical cancer incidence so as to model past trends, to estimate the impact of cervical screening on cervical cancer rates at different ages and to obtain a counterfactual baseline under a no-screening scenario. Trend analysis of cancer registry data recorded between 1971 and 2013. England. 132 493 women aged 20-84 with a diagnosis of cervical cancer. Cervical cancer incidence data were modelled using a modified age period cohort model able to capture both increased exposure to human papillomavirus (HPV) as well as changes in the age of exposure to HPV in young cohorts. Observed rates were compared with counterfactual baseline rates under a no-screening scenario to estimate the protective effect of screening. Rates of cervical cancer incidence have been decreasing since the introduction of screening but are projected to increase in the future under the current scenario. Between 1988 and 2013, it was estimated that screening had prevented approximately 65 000 cancers. Moreover, in 2013, the age-standardised rate (ASR) estimated under the no-screening scenario (37.9, 95% CI 37.4 to 38.3) was threefold higher among women aged 20-84 than the observed ASR (12.8, 95% CI 12.3 to 13.3). We estimate that the age of first HPV exposure has decreased by about 1 year every decade since the early 1970s (women born in 1955 onwards). Our results corroborated the importance of screening in preventing cervical cancer and indicated future rates are dependent on age at HPV exposure. Estimated future rates can be used for healthcare planning while the counterfactual baseline to quantify the impact of HPV vaccination in microsimulations.

Identifiants

pubmed: 30679300
pii: bmjopen-2018-026292
doi: 10.1136/bmjopen-2018-026292
pmc: PMC6347909
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026292

Subventions

Organisme : Cancer Research UK
ID : C8162/A16892
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Int J Cancer. 2012 Jun 1;130(11):2638-44
pubmed: 21702036
Br J Cancer. 2003 Jul 7;89(1):88-93
pubmed: 12838306
Br J Cancer. 2014 Aug 26;111(5):965-9
pubmed: 24992581
Br J Cancer. 2016 Oct 25;115(9):1140-1146
pubmed: 27632376
J Med Screen. 2017 Jun;24(2):110-112
pubmed: 27363972
Int J Cancer. 2018 Feb 15;142(4):709-718
pubmed: 29023748
Genitourin Med. 1997 Oct;73(5):365-7
pubmed: 9534745
BJOG. 2001 Apr;108(4):388-95
pubmed: 11305546
BMJ. 2009 Jul 28;339:b2968
pubmed: 19638651
Br J Cancer. 2013 Jul 9;109(1):35-41
pubmed: 23820257
Eur J Cancer. 2013 Oct;49(15):3262-73
pubmed: 23751569
Eur J Cancer. 1996 May;32A(5):836-41
pubmed: 9081363
Cancer Epidemiol. 2015 Dec;39(6):1152-6
pubmed: 26514971
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Br J Cancer. 2016 Oct 25;115(9):1147-1155
pubmed: 27727232
Br J Cancer. 2000 Sep;83(5):561-5
pubmed: 10944591
Stat Med. 2003 Sep 15;22(17):2751-66
pubmed: 12939784
Lancet Oncol. 2016 Oct;17(10):1445-1452
pubmed: 27567054
J Natl Cancer Inst. 2008 May 7;100(9):622-9
pubmed: 18445828
Br J Cancer. 2004 May 4;90(9):1784-6
pubmed: 15150597
J Med Screen. 2012 Sep;19(3):127-32
pubmed: 23093730
Lancet. 2013 Nov 30;382(9907):1781-94
pubmed: 24286784
Br J Cancer. 2011 Jun 28;105(1):177-84
pubmed: 21654675
PLoS Med. 2014 Jan;11(1):e1001585
pubmed: 24453946
J Med Screen. 2012 Jun;19(2):89-93
pubmed: 22653575
Prev Med. 2018 Feb;107:21-28
pubmed: 29247658
J Clin Invest. 2016 Jan;126(1):5-11
pubmed: 26727228
Lancet Public Health. 2018 Jan;3(1):e34-e43
pubmed: 29307386
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1354-61
pubmed: 22665576

Auteurs

Francesca Pesola (F)

School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Peter Sasieni (P)

School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH